VTWO: Highly Diversified Portfolio Of Small Caps Fails To Generate Lucrative Return
Summary
- Vanguard Russell 2000 ETF invests in growth and value stocks of small-cap companies, offering potential for strong capital growth.
- The fund has a low yield and average total return, but performed well during the high-growth period between 2016 and 2021.
- Concerns about future price performance due to the possibility of a recession and limited potential for significant returns.
- Looking for more investing ideas like this one? Get them exclusively at The Total Pharma Tracker. Learn More »
anyaberkut
~ by Snehasish Chaudhuri, MBA (Finance)
Vanguard Russell 2000 ETF (NASDAQ:VTWO) is an exchange-traded fund that invests in growth and value stocks of small-cap companies. It invests in a large pool of stocks operating across diversified sectors. This often-overlooked asset class has the potential of generating strong capital growth because these firms are also strong acquisition targets. Small-cap stocks by their very nature are a little bit riskier than their large-cap peers. This fund generates low yield and total return is quite average around 7 to 8 percent. However, total return has been strong during the high-growth period between 2016 and 2021. The fund generated an annual average total return of 14.3 percent during that time. However, there is some concern about the future price performance of this fund, as small-cap funds may not witness any growth if there is a recession.
VTWO Invests a Small Proportion of Its Assets in a Large Pool of Small Caps
Vanguard Russell 2000 ETF was launched and is managed by The Vanguard Group, Inc. It seeks to track the performance of the Vanguard Russell 2000 Index which is designed to measure the performance of small-cap stocks listed in the equity markets of the United States. VTWO replicates the Russell 2000 Index by investing all of its assets in the stocks in the same proportion in which it makes up the index. The fund invests in a large pool (more than 2000) of stocks, and thus a very small portion of its assets is invested in a particular stock. Top 10 holdings account for less than 3 percent of its entire portfolio.
In Absence of Strong Yield, VTWO Became Unattractive After Its Recent Price Rally
Vanguard Russell 2000 ETF was formed on September 20, 2010, and has been offering consistent quarterly pay-outs since the 3rd quarter of 2015. However, annual Vanguard Russell 2000 Index Fund ETF Shares (VTWO) Dividend Yield has been considerably low within the range of 1 to 1.5 percent. Almost two-third of its $6.24 billion AUM is invested in five sectors - financial, healthcare, industrial, consumer discretionary, information & communication technology (ICT). I believe these sectors have high growth prospects in the coming decade. VTWO also has a very low expense ratio of 0.1 percent, which makes diversified investments easier in funds involving only small-cap stocks.
As the economy starts recovering and the corporate earnings are largely constructive, it all comes down to VTWO's capacity to recover its earnings power, and the speed with which it is able to do so. But after its recent rally (a price growth of 7 percent in 2023), VTWO's portfolio becomes unattractive. Thus, VTWO’s price rally seems to have run out of steam. In a nutshell, despite having decent growth potential, the fund is not an attractive investment option.
Investability of VTWO according to My "7 Factor Model for Evaluating Global Funds"
VTWO’s long-term yields are lower than the current rate of inflation. Vanguard Russell 2000 ETF offers high potential for investment growth; share value typically rises and falls more sharply than that of funds holding bonds. VTWO's upside potential is modest, which is not good enough to justify buying fresh units of this fund at its current valuation. I would like to find out VTWO’s investability by applying my "7 Factor Model for Evaluating Diversified Funds."
Through "7 Factor Model for Evaluating Equity Funds," I try to assess whether the fund qualifies with respect to some basic criteria such as assets under management of $200 million, yield of 4 percent, current market price of $5, and diversification of its investments among eight major sectors - technology, financial, healthcare, industrial, energy & materials, real estate, consumer products and utilities. Degree of discount from its current net asset value, risk of its current portfolio, and sustainability of its current yield are the remaining 3 factors that ultimately helps me to assess the attractiveness of Vanguard Russell 2000 ETF for both its income-seeking and growth-seeking investors.
Investment Thesis
I find Vanguard Russell 2000 ETF is not an attractive fund according to my "7 Factor Model for Evaluating Diversified Funds." It qualifies for the minimum requirements with respect to AUM of $200 million, stock price of $5, and has a decent overall return of around 7 percent over the longer term. During the 5-year period between 2016 and 2021, the annual average total return was more than 14 percent. It has a very low expense ratio, which enables investors to benefit from a highly diversified portfolio. The portfolio is well-diversified and carries a relatively low level of risk. VTWO invests the majority of its assets in four sectors (ICT, financial, technology, industrial) that have high-growth potential.
However, there is some concern about the future price performance of this fund, as small-cap funds may not witness any growth if there is a global recession. Small-cap stocks usually are traded less than their large-cap peers. There is also the possibility of these small caps not generating significant returns over the long run. A low turnover ratio of 19 percent also doesn’t provide much scope for an overhaul of its portfolio. Moreover, the fund generates a very low yield around 1.2 percent. In the absence of price growth, VTWO’s yield will not be sufficient enough to beat even the current level of inflation. It is also currently trading at par with its net asset value of $75.05. Thus, I would suggest a hold for the investors of Vanguard Russell 2000 ETF.
About the TPT service
Thanks for reading. At the Total Pharma Tracker, we offer the following:-
Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material.
For investors requiring hands-on support, our in-house experts go through our tools and find the best investible stocks, complete with buy/sell strategies and alerts.
Sign up now for our free trial, request access to our tools, and find out, at no cost to you, what we can do for you.
This article was written by
Dr Dutta is a retired veterinary surgeon. He has over 40 years experience in the industry. Dr Maiya is a well-known oncologist who has 30 years in the medical field, including as Medical Director of various healthcare institutions. Both doctors are also avid private investors. They are assisted by a number of finance professionals in developing this service.
If you want to check out our service, go here - https://seekingalpha.com/author/avisol-capital-partners/research
Disclaimer - we are not investment advisors.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.